Griffith M J, Reisner H M, Lundblad R L, Roberts H R
Thromb Res. 1982 Aug 1;27(3):289-301. doi: 10.1016/0049-3848(82)90076-7.
To determine the functional properties of factor IX isolated from the plasma of CRM+ hemophilia B patients, an assay system using proteins isolated from human plasma had to be developed which would be amenable to kinetic studies under a variety of experimental conditions. The present study describes the activation of factor X by factor IXa, isolated from normal human plasma, in an assay system which allows manipulation of calcium, phospholipid and factor VIIIa concentrations. Initial rate measurements with factor VIIIa present in the system were made by incubating factor VIII with factor Xa immediately before factor IXa assay. With this approach, the initial rate of factor X activation was constant, with little evidence for a lag period. Within the framework of the assay system described in the present study, it should be possible to examine not only genetic variants of factor IX, but also variants of factor VIII, as well as providing a means of routine factor IXa and factor VIII(a) assays.
为了确定从CRM + B型血友病患者血浆中分离出的凝血因子IX的功能特性,必须开发一种使用从人血浆中分离出的蛋白质的检测系统,该系统应适合在各种实验条件下进行动力学研究。本研究描述了在一个可以控制钙、磷脂和凝血因子VIIIa浓度的检测系统中,从正常人血浆中分离出的凝血因子IXa对凝血因子X的激活作用。在检测凝血因子IXa之前,通过立即将凝血因子VIII与凝血因子Xa孵育,对系统中存在凝血因子VIIIa时的初始速率进行测量。采用这种方法,凝血因子X激活的初始速率是恒定的,几乎没有延迟期的证据。在本研究所述检测系统的框架内,不仅应该能够检测凝血因子IX的基因变体,还能够检测凝血因子VIII的变体,同时还能提供一种常规检测凝血因子IXa和凝血因子VIII(a)的方法。